DE60045750D1 - E5564 zur Verwendung in der Behandlung von Allograft-Abstossung oder Host-versus-Graft-Erkrankungen - Google Patents

E5564 zur Verwendung in der Behandlung von Allograft-Abstossung oder Host-versus-Graft-Erkrankungen

Info

Publication number
DE60045750D1
DE60045750D1 DE60045750T DE60045750T DE60045750D1 DE 60045750 D1 DE60045750 D1 DE 60045750D1 DE 60045750 T DE60045750 T DE 60045750T DE 60045750 T DE60045750 T DE 60045750T DE 60045750 D1 DE60045750 D1 DE 60045750D1
Authority
DE
Germany
Prior art keywords
treatment
allograft rejection
host versus
versus graft
graft disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60045750T
Other languages
English (en)
Inventor
Daniel P Rossignol
Melvyn Lynn
William D Kerns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Application granted granted Critical
Publication of DE60045750D1 publication Critical patent/DE60045750D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60045750T 1999-01-14 2000-01-14 E5564 zur Verwendung in der Behandlung von Allograft-Abstossung oder Host-versus-Graft-Erkrankungen Expired - Lifetime DE60045750D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11620299P 1999-01-14 1999-01-14

Publications (1)

Publication Number Publication Date
DE60045750D1 true DE60045750D1 (de) 2011-04-28

Family

ID=22365882

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60045750T Expired - Lifetime DE60045750D1 (de) 1999-01-14 2000-01-14 E5564 zur Verwendung in der Behandlung von Allograft-Abstossung oder Host-versus-Graft-Erkrankungen
DE60036790T Expired - Lifetime DE60036790T2 (de) 1999-01-14 2000-01-14 Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60036790T Expired - Lifetime DE60036790T2 (de) 1999-01-14 2000-01-14 Verwendung von e5564 zur behandlung von sepsis durch intravenöse infusion

Country Status (11)

Country Link
EP (3) EP1158990B1 (de)
JP (1) JP2002534471A (de)
AT (2) ATE501760T1 (de)
AU (1) AU2614400A (de)
CA (1) CA2359478A1 (de)
CY (1) CY1108039T1 (de)
DE (2) DE60045750D1 (de)
DK (1) DK1158990T3 (de)
ES (1) ES2291188T3 (de)
PT (1) PT1158990E (de)
WO (1) WO2000041703A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105033A1 (en) 2000-06-09 2003-06-05 Rossignol Daniel P. Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US20020042379A1 (en) * 2000-06-09 2002-04-11 Daniel Rossignol Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
AU2002323106A1 (en) * 2001-08-10 2003-02-24 Eisai Co., Ltd. Treatment and prevention of heat shock protein-associated diseases and conditions
US10857197B2 (en) 2014-12-12 2020-12-08 The Feinstein Institutes For Medical Research Treatment of HMGB1-mediated inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530113A (en) 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
US5681824A (en) * 1995-06-05 1997-10-28 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia

Also Published As

Publication number Publication date
ES2291188T3 (es) 2008-03-01
EP1158990B1 (de) 2007-10-17
WO2000041703A1 (en) 2000-07-20
EP2298326A2 (de) 2011-03-23
DK1158990T3 (da) 2008-01-28
EP1158990A1 (de) 2001-12-05
EP1867336A2 (de) 2007-12-19
EP1867336A3 (de) 2008-04-23
DE60036790T2 (de) 2008-07-24
ATE375798T1 (de) 2007-11-15
EP2298326A3 (de) 2011-04-27
PT1158990E (pt) 2007-12-21
AU2614400A (en) 2000-08-01
CY1108039T1 (el) 2013-09-04
EP1158990A4 (de) 2003-08-13
CA2359478A1 (en) 2000-07-20
ATE501760T1 (de) 2011-04-15
EP1867336B1 (de) 2011-03-16
DE60036790D1 (de) 2007-11-29
JP2002534471A (ja) 2002-10-15

Similar Documents

Publication Publication Date Title
ATE246197T1 (de) Neue heteroaromatische fructose 1,6- bisphosphatase inhibitoren
FR12C0004I1 (de)
ATE350385T1 (de) Neue aryl fructose-1,6-bisphosphatase inhibitoren
HUP9700368A2 (hu) II-típusú diabetes mellitus kezelése amilin agonistákkal
ATE330630T1 (de) Antikoagulierende humanisierte antikörper gegen faktor ix, zur verwendung in der behandlung von thrombose
DE60030277D1 (de) ANORDNUNGEN, SYSTEME UND VERFAHREN ZUR BEHANDLUNG VON BIOLOGISCHEN FLüSSIGKEITEN MIT LICHT
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE69226835D1 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus, hypoglykämie und anderer krankhafter zustände
DE60229406D1 (de) Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
MX9307886A (es) Composicion farmaceutica y proceso para su preparacion.
TR200102864T2 (tr) N”rolojik ya da n”ropsikiyatrik bozukluklarìn tedavisi i‡in y”ntem
DE60045750D1 (de) E5564 zur Verwendung in der Behandlung von Allograft-Abstossung oder Host-versus-Graft-Erkrankungen
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE209914T1 (de) Verwendung von pyridylmethylsulfinyl-1h- benzimidazol derivaten zur behandlung durch helicobacter verursachter erkrankungen
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
EA199800821A1 (ru) Способ лечения аутизма
ES2082212T3 (es) Nuevos inhibidores de alfa-glucosidasa.
DE69111457D1 (de) Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien.
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
EA199800822A1 (ru) Способ лечения избыточной агрессии
WO2001093921A3 (en) Administration of an anti-endotoxin drug by bolus or intermittent intravenous infusion